Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors

NCT07444814 is registered in ClinicalTrials.gov with Whitehawk Therapeutics, Inc. as lead sponsor.

NCT NCT07444814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07444814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors
Lead sponsor
Whitehawk Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 19, 2025
Completion date
December 31, 2028
Enrollment
226 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, non-squamous egfr wt nsclc, ovarian cancer, ovarian cancer metastatic, ovarian cancer metastatic recurrent, platinum resistant ovarian cancer, proc